New AI model improves prediction of cancer immunotherapy success - News-Medical

Ah, Harvard Medical School has blessed us with COMPASS, an AI model that improves prediction of cancer immunotherapy success by 8.5%. Because nothing says 'breakthrough' like moving the needle by less than a tenth. Of course, that 8.5% improvement comes with the usual caveats: it's a research paper, not a clinic. The real world has a habit of flattening those percentages. But never mind — let's celebrate the number.

The researchers compared COMPASS to existing approaches and found it outperformed them by that tidy 8.5%. Which existing approaches? The kind that already leave doctors shrugging. The model analyses patient data to predict immunotherapy response — a task currently performed by oncologists using their 'gut feeling' and a few biomarkers. So yes, AI is slightly better than guesswork. Progress!

Meanwhile, patients are left hoping that the model's predictions actually translate to outcomes. But why worry? We have a shiny new AI model named COMPASS. Point us north, digital saviour. Because that's always worked before.